Abstract Details

Title Premature Brain Aging and Choroid Plexus Enlargement in Young Adults with Psychosis

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) S42 - Perspectives on Non-Alzheimer's Dementia Diagnostics and Therapeutics (1:24 PM-1:36 PM)

Poster/Presentation
Number 003

Objective A higher-than-expected rate of cerebral aging has been reported in individuals with neuropsychiatric disorders, but remains poorly understood. We aimed to investigate whether a premature brain aging phenotype exists in young individuals with psychosis.

Background The Regional Vulnerability Index for Alzheimer’s Disease (RVI-AD) quantifies how closely an individual’s brain resembles Alzheimer’s-like aging patterns, providing a biomarker of structural aging. The choroid plexus (ChP), a cerebrospinal fluid (CSF)–producing and immune-regulating structure, enlarges with age and has been linked to neurodegenerative conditions. Both RVI-AD and ChP morphology are linked to biological aging in healthy and neurodegenerative populations; however, their relevance to psychosis remains unexplored. Investigating these associations may clarify how immune–CSF alterations are related to brain aging patterns in early psychosis.

Design/Methods T1-weighted 3T MRI data from 60 participants (ages 17–36; 47 psychosis spectrum, 13 controls) from the Human Connectome Project for Early Psychosis dataset were analyzed. ChP volumes were manually segmented (inter-rater ICC = 0.87), adjusted for intracranial volume, and standardized into z-scores. Linear regression models were used to (1) compare groups on RVI-AD and ChP volume and (2) examine associations between ChP volume and AD-RVI within the psychosis group, adjusting for age, sex, socioeconomic status, and site.

Results

Participants with psychosis demonstrated significantly higher RVI-AD (β = 0.79, p = 0.02) than controls, consistent with age-related brain patterns, with no ChP volume differences. Within the psychosis group, greater ChP volume was positively associated with higher RVI-AD (β = 0.40, p = 0.003).

Conclusions Individuals with psychosis exhibited increased age-related structural brain signatures, observed already in early adulthood. The positive association between RVI-AD and ChP volumes likely suggests overlapping immune and structural processes contributing to premature brain aging. Ongoing analyses in an expanded cohort (n = 120) with inflammatory and clinical measures will further explore neuroimmune pathways in early aging trajectories of psychosis.

Authors/Disclosures
Neslihan Yildiz Ozhan, MD PRESENTER	Dr. Yildiz Ozhan has nothing to disclose.
Richard Rushmore, PhD	Prof. Rushmore has nothing to disclose.
Suheyla Cetin-Karayumak, PhD	Dr. Cetin-Karayumak has nothing to disclose.
Yogesh Rathi, PhD	The institution of Dr. Rathi has received research support from NIH.
Michael Coleman	Mr. Coleman has nothing to disclose.
Sylvain Bouix, PhD	Mr. Bouix has nothing to disclose.
T B	Mr. B has nothing to disclose.
Yuan Gao	Miss Gao has nothing to disclose.
Bhim Adhikari, PhD	Dr. Adhikari has nothing to disclose.
peter kochunov, PhD	Prof. kochunov has nothing to disclose.
Cornelius Berberich, MD, PhD	Dr. Berberich has nothing to disclose.
Ofer Pasternak, PhD	The institution of Dr. Pasternak has received research support from NIH. The institution of Dr. Pasternak has received research support from Michael J Fox Foundation.
Daphne Holt, MD, PhD	Dr. Holt has nothing to disclose.
Matcheri S. Keshavan, MD	Dr. Keshavan has nothing to disclose.
Dost Ongur, MD, PhD	Dr. Ongur has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BD2. Dr. Ongur has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JAMA Network. The institution of Dr. Ongur has received research support from NIH. Dr. Ongur has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker at conference with Boehringer Ingelheim.
alan breier, MD	Dr. breier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clexio Therapeutics . Dr. breier has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neumarker . Dr. breier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bristol Meyer Sqibb. Dr. breier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Terran Bioscience .
Martha Shenton	Martha Shenton has nothing to disclose.
Marek Kubicki, MD, PhD	The institution of Prof. Kubicki has received research support from NIH.
Johanna Seitz-Holland, MD, PhD	Dr. Seitz-Holland has nothing to disclose.

��ɫ��

��ɫ��